Heike Benes

Schwerin, MV, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Correction to: SURWEY real-world study of solriamfetol: initiation, titration, safety, efficacy, and follow-up experience for patients with obstructive sleep apnea in Germany.

Correction to: SURWEY real-world study of solriamfetol: initiation, titration, safety, efficacy, and follow-up experience for patients with obstructive sleep apnea in Germany.

Journal: Sleep & breathing = Schlaf & Atmung

Published: April 09, 2025

A randomised crossover trial of daridorexant for the treatment of chronic insomnia and nocturia.

A randomised crossover trial of daridorexant for the treatment of chronic insomnia and nocturia.

Journal: Journal of sleep research

Published: November 22, 2024

Patients with obstructive sleep apnea in Germany.

Patients with obstructive sleep apnea in Germany.

Journal: Sleep & breathing = Schlaf & Atmung

Published: September 12, 2024

Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial.

Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial.

Journal: Molecular psychiatry

Published: December 14, 2023

Summary of Research: Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ).

Summary of Research: Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ).

Journal: Advances in therapy

Published: December 21, 2022

Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.

Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.

Journal: CNS drugs

Published: December 01, 2022

Solriamfetol real world experience study (SURWEY): Initiation, titration, safety, effectiveness, and experience during follow-up for patients with narcolepsy from Germany.

Solriamfetol real world experience study (SURWEY): Initiation, titration, safety, effectiveness, and experience during follow-up for patients with narcolepsy from Germany.

Journal: Sleep medicine

Published: October 14, 2022

Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder.

Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder.

Journal: Translational psychiatry

Published: June 06, 2022

Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ).

Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ).

Journal: The patient

Published: October 13, 2020

Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial.

Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial.

Journal: Annals of the American Thoracic Society

Published: May 01, 2020

An algorithm for actigraphy-based sleep/wake scoring: Comparison with polysomnography.

An algorithm for actigraphy-based sleep/wake scoring: Comparison with polysomnography.

Journal: Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology

Published: February 07, 2020

A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.

A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.

Journal: Journal of psychopharmacology (Oxford, England)

Published: June 01, 2018

Showing 1-12 of 32

Last Updated: 09/26/2026